Literature DB >> 16256878

Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese.

Toru Kubo1, Hiroaki Kitaoka, Makoto Okawa, Yoshihisa Matsumura, Nobuhiko Hitomi, Naohito Yamasaki, Takashi Furuno, Jun Takata, Masanori Nishinaga, Akinori Kimura, Yoshinori L Doi.   

Abstract

OBJECTIVES: We studied the longitudinal evolution of hypertrophic cardiomyopathy (HCM) caused by a founder frameshift mutation in the cardiac myosin-binding protein C (MyBPC) gene.
BACKGROUND: Mutations in the MyBPC gene have been associated with delayed expression of HCM and a good prognosis. Few studies, however, demonstrated the phenotype-genotype correlations in the longitudinal study.
METHODS: We studied long-term evolution of clinical features of 15 unrelated families who were found to have an identical frameshift mutation in the MyBPC gene: a one-base deletion of a thymidine at nucleotide 11645 (V592fs/8).
RESULTS: Thirty-nine individuals in 15 families were genotype-positive. Thirty of the 39 individuals with the mutation were phenotype-positive. The disease penetrance was 100% in subjects > or =50 years and 65% in those <50 years. "End-stage" HCM (ejection fraction <50%) was observed in 7 (18%) of the 39 genotype-positive individuals (7 [23%] of the 30 phenotype-positive patients); 6 of them were 60 years or older. Seven patients were hospitalized for treatment of repeated congestive heart failure, and four patients died or had implantable cardioverter-defibrillator discharge (13%; incidence, 1.4%/year) during a mean follow-up period of 9.2 +/- 5.5 years.
CONCLUSIONS: Elderly patients with a V592fs/8 mutation in the MyBPC gene may evolve into the "end-stage" HCM, characterized by left ventricular systolic dysfunction, cavity dilation, and irreversible heart failure. The clinical course in patients with this mutation is not benign in the long run, with progressive left ventricular remodeling with advancing age.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16256878     DOI: 10.1016/j.jacc.2005.05.087

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

1.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Screening of sarcomere gene mutations in young athletes with abnormal findings in electrocardiography: identification of a MYH7 mutation and MYBPC3 mutations.

Authors:  Chika Kadota; Takuro Arimura; Takeharu Hayashi; Taeko K Naruse; Sachio Kawai; Akinori Kimura
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

4.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

Review 5.  Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.

Authors:  Lucie Carrier; Giulia Mearini; Konstantina Stathopoulou; Friederike Cuello
Journal:  Gene       Date:  2015-09-08       Impact factor: 3.688

6.  Limited distribution of a cardiomyopathy-associated variant in India.

Authors:  Tatum S Simonson; Yuhua Zhang; Chad D Huff; Jinchuan Xing; W Scott Watkins; David J Witherspoon; Scott R Woodward; Lynn B Jorde
Journal:  Ann Hum Genet       Date:  2010-02-18       Impact factor: 1.670

Review 7.  Signaling and myosin-binding protein C.

Authors:  Jeanne James; Jeffrey Robbins
Journal:  J Biol Chem       Date:  2011-01-21       Impact factor: 5.157

Review 8.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

Review 9.  Genetic determinants of cardiac hypertrophy.

Authors:  Ali J Marian
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

10.  Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience.

Authors:  M Michels; Y M Hoedemaekers; M J Kofflard; I Frohn-Mulder; D Dooijes; D Majoor-Krakauer; F J Ten Cate
Journal:  Neth Heart J       Date:  2007-05       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.